September 30, 2018 March 31, 2018 Assets (Note 2) Current assets: Cash $ 1,659 $ 7,194
Urovant’s second product candidate, hMaxi-K, is a novel gene therapy being developed for patients with OAB who have failed oral pharmacological therapy. Urovant intends to develop treatments for DESCRIPTION (provided by applicant): This grant application is by Ion Channel Innovations, LLC, (ICI) a company dedicated to the development of naked DNA transfer to treat the unmet needs of people with common smooth muscle diseases that negatively impactthe quality of life of millions. hMaxi-K has been evaluated in two Phase 1 studies in OAB patients including a Urovant disclaims any obligation to update these forward-looking statements, except as may be required by law. Sep 24, 2018 · Urovant's second product candidate, hMaxi-K, is a novel gene therapy being developed for patients with OAB who have failed oral pharmacological therapy. Urovant intends to develop treatments for
Jan 03, 2019 · Urovant has licensed global rights, excluding Japan and certain Asian territories, for the development and commercialization of vibegron. Urovant’s second product candidate, hMaxi-K, is a novel gene therapy being developed for patients with OAB who have failed oral pharmacological therapy.
May 15, 2008 · Maxi-K gene therapy may be a safe and effective future option for men whose erectile dysfunction is not treatable with oral therapy. Maxi-K therapy is a unique, locally administrated gene-transfer hMaxi-K gene therapy - Sumitovant Biopharma Alternative Names: hMaxi-K - Ion Channel Innovations; hMaxi-K; pVAX/hSlo; URO-902 Latest Information Update: 06 Feb 2020 Patients given tlie two highest doses of hMaxi-K had apparent sustained improvements in erectile function (EF) as indicated by improved HEF-EF domain scores over the length of the study. One
40. Long-Term Results of a Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Safety and Potential Activity of Escalating Doses of hMaxi-K Gene Transfer in Female Participants with Overactive Bladder and Detrusor Overactivity Page S16 Download PDF
September 30, 2018 March 31, 2018 Assets (Note 2) Current assets: Cash $ 1,659 $ 7,194 Nov 12, 2018 · Urovant has licensed global rights, excluding Japan and certain Asian territories, for the development and commercialization of vibegron. Urovant’s second product candidate, hMaxi-K, is a novel gene therapy being developed for patients with OAB who have failed oral pharmacological therapy. hMaxi-K has been evaluated in two Phase 1 studies in OAB patients including a small, double-blind, placebo-controlled Phase 1b clinical trial as an intravesical injection in women with overactive bladder symptoms. Ion Channel Innovations completed the Phase 1b study in 2017 and found hMaxi-K to be generally well tolerated. territories, for the development and commercialization of vibegron. Urovant s second product candidate, hMaxi-K, is a novel gene therapy being developed for patients with OAB who have failed oral pharmacological therapy. Urovant intends to develop treatments for additional urologic diseases. For more information, please visit www.urovant.com . Nov 08, 2018 · BASEL, Switzerland & IRVINE, Calif.--(BUSINESS WIRE)--Nov 8, 2018--Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing novel therapies for urologic conditions, today announced it completed enrollment in its international Phase 3 clinical trial, EMPOWUR, evaluating the safety and efficacy of vibegron as a treatment for adults with symptoms of